Please login to the form below

Blueprint for healthcare: Brand strategy and planning

This Blueprint for healthcare: brand strategy and planning pack contains two new tools for developing a stakeholder-centric brand, that patients and their HCP's want and need

A brand lives in the heart and mind of its audience as a sum of experiences. Every engagement presents an opportunity to deliver a positive experience and suboptimal experiences have a lasting impact on the brand.

When pharmaceutical and biotech companies are working on brand strategy and brand planning it is vital that they take an ‘outside-in view’ and understand what makes their healthcare customers tick.

Only when they are armed with patient, HCP and other stakeholder insights can they ensure that their pharmaceutical brand positioning can deliver against those customer needs and provide a successful customer-centric and multichannel experience.

To help companies to do this, Blue Latitude Health has developed an innovative two-part brand strategy and planning pack; that’s based around its new ‘Four Corners of Brand Experience’ approach for campaign management. Grounded in consumer and FMCG marketing, where the perception of a brand is based on experiences, the ‘Four Corners’ approach acknowledges the similarities those sectors have with the pharmaceutical industry as well as the differences.

Alongside the framework, is a checklist of 50 questions, a brand team needs to ask, in order to deliver customer-centric multichannel campaigns efficiently and effectively. The questions are grouped around the five stages of brand planning:

1. Operations and set up

2. Insight

3. Planning

4. Execution

5. Measurement

It also allows for differing approaches based on product lifecycle, including pre-launch and established products.

Blue Latitude Health, developed these practical tools, while working with the top pharma and biotech organisations and brands across the globe to develop customer centric brand strategy and integrated multichannel campaigns, driving behaviour change and brand loyalty. Download this pack to benefit from this knowledge.

DOWNLOAD THE FULL PACK HERE

4th July 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

The changing face of pharma in the precision era
Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. Here, she reveals what pharmaceutical companies need to do to prepare to bring precision medicines to market and how she is ensuring the patient is consulted every step of the way.
Blue Latitude Health
Creative problem solving, solved
Customer Experience Consultant Eimear Power explains how pharma teams can unlock their creativity and foster truly innovative ideas.
Blue Latitude Health
Three strategies for managing loss of exclusivity successfully
Claire Taylor, Senior Associate Consultant at Blue Latitude Health explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
Blue Latitude Health
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
Blue Latitude Health
Diagnosing the lag in neuropsychiatric treatments
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
Blue Latitude Health